07.05.2025
Arctic Bioscience has today released its Annual Report 2024, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 6th of May 2025.
On 27 February 2025 Arctic Bioscience reported preliminary and unaudited key results for the fourth quarter and full year 2024. Today’s audited accounts include adjustments to gross profit and gross margin due to extraordinary cost provisions of NOK 2,34 million in relation to recall of goods sold to business partners in Q4 2024. The recall issue arose late Q1 2025 and is undergoing standard quality procedures.
The report is attached to this stock notice and is available on the company’s website.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.